Biotechnology

With a sub-$10M market cap and blockbuster data, IMUNON's CEO faces a critical test: convince Wall Street its ovarian cancer drug is the real deal.

After a stunning FDA reversal for its Huntington's drug, uniQure seeks $150M. A look at the high-stakes financing behind a pipeline of hope and risk.

Ottawa's quiet $892K investment in a Vancouver biotech firm is more than a grant; it's a calculated move to secure Canada's food supply from a post-antibiotic crisis.

New 2- and 3-year data shows lebrikizumab sustains skin clearance with less frequent dosing, offering patients flexibility and positioning Eli Lilly for a major market share.

For bladder cancer patients facing bladder removal, a novel therapy from Sweden offers new hope. A US trial expansion targets the most resistant cases.

With a new brand and $1B in state funding, Indiana is unifying its massive bioscience sector to challenge global hubs like Boston. Is 'BioHeartland' the real deal?

A projected 12.4% CAGR signals a boom in hematopoietic stem cell transplantation, but the real story lies in the science poised to overcome timeless hurdles.

Integral Molecular wins another 'Top Workplace' award, but the real story is how its people-first culture is fueling scientific breakthroughs and building a city.

Parexel's new biotech incubator isn't just another funding vehicle. It's a strategic move to embed regulatory expertise at the seed stage, betting that early guidance is more valuable than capital alone.

A new patent for 3D fibroblast spheroids could revolutionize chronic wound treatment, giving FibroBiologics a key edge in the burgeoning biotech market.

As Kyverna eyes a first-in-class approval for its CAR T-cell therapy, it brings in a legal and compliance veteran with a prosecutor's edge to clear the path.

With compelling Phase 2b survival data, NeuroSense is advancing its multi-target ALS drug to a pivotal Phase 3 trial. A deep dive into the science and strategy.

bioAffinity Technologies' new gene-silencing therapy kills common skin cancer cells in lab studies while leaving healthy cells untouched, hinting at a future without scars.

A new pharma deal isn't just about medicine. It's about the AI-driven network set to dismantle the slow, costly system of drug discovery as we know it.

Prolium Bioscience advances its T-cell engager, PRO-203, in trials for scleroderma and lupus, heralding a new, potent strategy against severe autoimmunity.

With a pivotal drug approval on the horizon, Spruce Biosciences' appointment of a rare disease veteran signals a critical transition from R&D to commercial reality.

Praxis Precision Medicines' elsunersen earns Breakthrough Therapy status, signaling a major step toward the first disease-modifying treatment for SCN2A-DEE.

Australian radiopharma innovator AdvanCell is planting its flag in Greater Boston with a new HQ and factory, a strategic move to scale its potent Lead-212 therapy.

A new prostate cancer drug is emerging from a powerful alliance. We deconstruct the strategic rationale behind the deal, revealing a model for the future.

With new funding from top VCs, DropGenie is shrinking gene editing to power the next wave of AI-driven drug discovery using precious patient cells.